The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.

Pfizer Inc. PFE shares are trading lower by almost 1% on Monday as the company shared data from Phase 2b studies of ...

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data ...

Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug ...

Roche Holding AG and Pfizer Inc. are aggressively advancing obesity and T2D pipelines to capture share in the surging GLP-1 ...

Pfizer (PFE) fell ~5% on Tuesday as Wall Street analysts assessed mid-stage data the company posted for its obesity therapy PF-08653944 ahead of its consensus-beating Q4 2025 results, which indicated ...

Pfizer highlighted the performance of a weight-loss drug it acquired in last year's deal to buy Metsera. Pfizer's stock closed 3% lower on Tuesday after investors were disappointed by limited midstage ...

Pfizer has received approval from the US Food and Drug Administration (FDA) for an expanded indication of Hympavzi ...

Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda ...